MedTrace Logo

CCR5-modified CD4+ T Cells for HIV Infection

NCT03666871 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-05-21

No results posted yet for this study

Summary

A Comparative Study of Autologous CD4+ T Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 versus ex vivo Expanded Unmodified Autologous CD4+ T Cells in Treated HIV-1 Infected Subjects

Conditions

  • HIV Infections

Interventions

BIOLOGICAL

SB-728-T

Autologous CD4+ T cells with ex vivo modification of the CCR5 gene by zinc finger nucleases

BIOLOGICAL

Expanded unmodified autologous CD4+ T cells

Autologous CD4+ T cells without ex vivo modification of the CCR5 gene by zinc finger nucleases

Sponsors & Collaborators

Principal Investigators

  • Carl Fichtenbaum, MD · University of Cincinnati

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-12
Primary Completion
2024-01-31
Completion
2024-02-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03666871 on ClinicalTrials.gov